Executive Summary
The endocrine-metabolic axis in polycystic ovary syndrome (PCOS) and in the context of fertility is potently modulated by insulin signaling and oxidative stress. This provides a strong rationale for designing products that combine insulin-sensitizing agents (inositols) with antioxidants (e.g., CoQ10, NAC, resveratrol) utilizing formats that offer high patient acceptability (e.g., sachets) and enhanced bioavailability (e.g., phospholipid carriers, SEDDS) [1–5].
Key Product and Formulation Insights:
Ratio:
The 40:1 ratio of myo-inositol (MI) to D-chiro-inositol (DCI) is the most clinically documented in comparisons of various proportions. It serves as a "physiological" approach in PCOS, demonstrating improvements in endocrine parameters, ovarian function, and insulin resistance [6, 7].
Dosing formats:
In practice, fixed-ratio unit doses are successfully achieved in formats such as sachets (e.g., 2 g MI + 50 mg DCI, twice daily), which facilitate ratio maintenance while reducing the pill burden [8].
DCI limits:
Excessive DCI doses present both clinical and reputational risks. Paradoxical deterioration of oocyte quality at high DCI doses and an increased number of immature oocytes have been reported in higher DCI dose cohorts. Furthermore, evidence indicates that DCI may act as an aromatase inhibitor, thereby increasing androgen levels [9–12].
Absorption:
"Inositol resistance" (affecting approximately 30–40% of patients) is primarily associated with impaired intestinal absorption. The co-administration of α-lactalbumin increases MI exposure (Cmax and AUC) and is described as a strategy to "rescue" the clinical response in non-responders [13, 14].
Mitochondrial support:
CoQ10 possesses robust clinical endpoints in the in vitro fertilization (IVF) domain: supplementation with 200 mg/day for 30–35 days increased CoQ10 content in follicular fluid and decreased the percentage of oxidized CoQ10, which correlated with improved oocyte fertilization rates [15].
Carrier technologies:
Phospholipid and emulsion-based technologies are highly instrumental for sensitive and/or poorly soluble ingredients. Liposomes can afford protection (e.g., shielding resveratrol from light and oxidation), while phytosomes can significantly enhance solubility and bioavailability (e.g., silymarin phytosome complex) [16, 17].
Lipid matrices:
High-payload lipid systems (SEDDS/S-SEDDS) and their solidification (e.g., via spray-drying, melt extrusion, adsorption onto solid carriers) provide a practical pathway for incorporating multiple lipophilic antioxidants into 1–2 daily doses, thereby improving stability and patient compliance [5, 18].
Clinical Context
PCOS serves as a clinical paradigm wherein the coupling of metabolism with hormonal axes is systemic in nature. Cited data indicate that ~70% of women with PCOS exhibit insulin resistance, ~80% are overweight/obese, and >50% develop type 2 diabetes mellitus (T2DM) and metabolic syndrome before the age of 40. This substantiates the necessity for targeted "endocrine-metabolic" formulations [2].
Mechanistically, MI and DCI function as secondary messengers for insulin. MI is associated with intracellular glucose transport, whereas DCI is linked to glycogen synthesis and storage, providing a biological rationale for their proportionate inclusion in products targeting insulin resistance and reproductive functions [2].
Concurrently, reproductive processes are highly sensitive to redox status. Oxidative stress and DNA damage arise from an imbalance between reactive oxygen species (ROS) and antioxidant defenses. Comprehensive literature reviews underscore the potential benefits of exogenous antioxidant treatment or CoQ10 supplementation, particularly in older women undergoing IVF [3].
Inositol Stereoisomers
Myo-inositol and D-chiro-inositol are inositol isomers demonstrating insulin-like properties. They act as secondary messengers in the insulin signaling pathway and are simultaneously associated with improvements in tissue insulin sensitivity and ovulatory function [1].
Clinical data emphasize that a combined MI + DCI supplement in a "physiological" 40:1 ratio can ameliorate the endocrine profile, ovarian function, and insulin resistance in PCOS patients [6]. In a study comparing multiple proportions (ranging from 1:3.5 to 80:1), the 40:1 ratio yielded the most significant results regarding ovulation restoration and the improvement of metabolic and hormonal parameters [7].
In the context of IVF-ET, data suggest that only the combined therapy was capable of enhancing oocyte and embryo quality, as well as pregnancy-related rates in women with PCOS [19]. Concurrently, the clinical risk of excessive DCI intake has been outlined: at increasing doses (e.g., 600–2400 mg/day), indications emerged that high DCI doses paradoxically impair oocyte quality and ovarian response, with the number of immature oocytes being significantly higher in cohorts receiving elevated DCI doses [9, 10].
An additional argument for safety and medical communication stems from the observation that DCI functions as an aromatase inhibitor, which increases androgen levels and may have deleterious consequences. This reinforces the necessity for "strictly defined" inositol supplements in PCOS management, rather than the use of arbitrary mixtures [11, 12].
Isomer Stabilization
The industrial challenge (maintaining sensitive isomer ratios, e.g., 40:1, within a uniform, high-yield matrix) practically resolves to unit dose control and mitigating the risk of DCI "overshooting." Sources indicate that selecting the appropriate MI/DCI ratio is critical to avoid DCI dose-dependent ovarian toxicity [20].
In "ready-to-mix" formats, the ratio is preserved through precise unit-dose design. In one cited regimen, each woman consumed a sachet twice daily containing 2 g of MI and 50 mg of DCI (a 40:1 ratio) [8]. Similarly, in a clinical trial, MI was administered in 2 g sachets dissolved in water twice daily, demonstrating that powder sachets are a highly compatible format for gram-level doses, capable of reducing the capsule count while maintaining strict dosing regimens [21].
In scenarios where the reproducibility of biological response and intestinal targeting are critical, an approach utilizing a gastro-resistant excipient and spray-drying has been presented. The engineered microparticles exhibited delayed release and a preferential MI release pattern (predominantly in the intestine) designed to control MI bioavailability. The authors explicitly stated the objective: to enhance MI bioavailability and minimize the variability of the biological response following oral administration [22]. In vitro/in situ data from this formulation demonstrated an approximately 3-fold increase in the Area Under the Curve (AUC) for MI (AUC MPs = 4.86 vs. AUC Inositol = 1.65), a parameter highly valuable for substantiating "medical food technologies" in B2B communication [22].
Regarding co-ingredients, an important tool for "effect stabilization" (in terms of clinical response) is α-lactalbumin. Evidence suggests that "inositol resistance" affects approximately 30–40% of patients, and non-responsiveness is primarily linked to impaired intestinal absorption. α-Lactalbumin is postulated to increase MI bioavailability by enhancing transepithelial transport, ensuring effective concentrations reach the systemic circulation and ovarian tissues [13]. Pharmacokinetic data revealed that the MI + α-LA combination increased MI Cmax and AUC by 35% and 31%, respectively, versus MI administered alone, providing a quantifiable rationale for designing products tailored for non-responders [14].
Liposomal and Phytosomal Delivery
For antioxidants and polyphenols, a significant barrier to efficacy in functional foods and supplements is limited aqueous solubility and degradation during gastrointestinal transit, which is explicitly identified as a limiting factor for systemic absorption. In this context, liposomes can serve as advanced carriers for a broad spectrum of bioactive compounds, while phytosomes function as phospholipid nanocarriers that markedly enhance the bioavailability of poorly water-soluble botanical ingredients [17, 23].
In the fertility/IVF domain, robust clinical-biochemical data pertain to CoQ10: supplementation with 200 mg/day for 30–35 days increased follicular fluid CoQ10 content to 0.49 µg/mL (+280%) and decreased the percentage of oxidized CoQ10 (27 ± 18% vs. 38 ± 24% in controls), resulting in an 88% fertilization rate of mature oocytes in the CoQ10 group (22/25) versus 74% in the control group (20/27) [15]. In an in vitro maturation (IVM) model, the addition of 50 µmol/L CoQ10 increased oocyte maturation rates and decreased aneuploidy in women aged 38–46 years, further reinforcing the mitochondrial-redox narrative for periconceptional products [24].
For vitamin E, a lipid antioxidant, there is a clinical rationale for synergy with CoQ10. The combined administration of CoQ10 and vitamin E resulted in improvements in fasting glycemia, insulin, HOMA-IR, SHBG, and total testosterone in PCOS patients. Furthermore, it was highlighted that vitamin E might augment oocyte protection against oxidative damage when co-administered with CoQ10 [25].
Regarding polyphenols, liposomal technology is presented as a tool for stabilization and protection. Liposomes have been shown to shield resveratrol from light and oxidation, increasing the quantity of the compound reaching the systemic circulation. However, after 20 days of storage at 4°C, liposome aggregation and the release of 8.92–15.26% of encapsulated compounds were observed, though coated liposomes exhibited lower leakage rates [16]. In the context of industrial solutions, such as the "waterless lipid matrix," platforms like Nutrateq claim to protect sensitive ingredients from the harsh gastric environment, offer enhanced stability due to anhydrous formulations, and improve absorption through phospholipids that form liposomes in the gastrointestinal tract [26].
For phytosomes, specific "proof-of-performance" parameters were demonstrated using silymarin. The phytosomal complex increased aqueous solubility (358.8 µg/mL vs. pure silymarin) and yielded a roughly 6-fold increase in systemic bioavailability. Process parameters for the optimized formulation were detailed (drug-to-phospholipid ratio 1:1.93; temperature 50°C; particle size ~218 nm; drug content ~90%) [17]. As a ready-to-market supplement example, a quercetin phytosome is described as "encased in a phospholipid sphere," boasting up to 20 times higher bioavailability versus standard quercetin [27].
High-Payload Matrices
Self-emulsifying drug delivery systems (SEDDS) are described as a well-established strategy to enhance the bioavailability of poorly water-soluble compounds. Being isotropic mixtures of oils, surfactants, and co-surfactants, they spontaneously form fine oil-in-water emulsions in gastrointestinal fluids, improving solubilization and absorption, a process aided by gastrointestinal motility [5, 28, 29]. Typical droplet size ranges have been reported (SEDDS 100–300 nm; SMEDDS <50 nm), along with associated mechanisms enhancing bioavailability (solubilization, droplet size reduction, potential lymphatic transport) [28, 29].
For "high-payload" systems, transitioning to a solid state is crucial. Progressing to solid SEDDS (S-SEDDS) resolves the limitations of liquid formulations, offering superior stability, scalability, and patient compliance. Solidification techniques encompass spray-drying, melt extrusion, and adsorption onto solid carriers [18]. Similarly, for liposomal systems, the feasibility of conversion into more stable powders via spray-drying or lyophilization in the presence of stabilizers (e.g., trehalose, sucrose, biopolymers) has been described, which helps maintain vesicle integrity during dehydration and rehydration [16].
In product development practice, "unification" entails selecting a format that accommodates grams of MI alongside lipophilic antioxidants and vitamins within 1–2 doses. Available market and formulation examples reveal three primary trajectories: (1) powders in sachets (e.g., MI 2 g twice daily in a clinical trial; or a sachet of 2 g MI + 50 mg DCI twice daily), (2) powders or free-flowing granules as supplements (e.g., a supplement in dispersible granules within a sachet), and (3) a "powder stick + capsules" format (e.g., a water-dispersible stick + a fish oil capsule as a daily serving) [8, 21, 30, 31].
Regarding the stabilization of lipophilic payloads concurrent with targeted intestinal release, sources describe platforms like Lipomatrix, featuring a molten fats core designed for "entrapping lipophilic compounds into a gastric-refractory environment," followed by emulsification upon exposure to duodenal fluids. The mechanism of gastric resistance involves ascorbyl palmitate remaining unionized in the stomach (pH < pKa), whereas in intestinal fluids (pH > pKa) it undergoes partial ionization, acting as a surfactant that facilitates emulsification and the formation of mixed micelles with bile salts [32].
Other Ingredients
Within the female endocrine-metabolic axis (particularly in PCOS), aside from MI/DCI, a significant role is played by ingredients targeting oxidative stress, inflammation, and insulin sensitivity. These include N-acetylcysteine (NAC), resveratrol, melatonin, CoQ10, and synergistic "partner nutrients" (e.g., chromium, folic acid) in multi-ingredient formulas [3, 4, 30, 33, 34].
NAC
NAC is described as a precursor to glutathione (a potent endogenous antioxidant) and a compound with antioxidant, anti-inflammatory, and insulin-sensitizing properties, which aligns with the pathophysiology of PCOS [4]. Clinical effect analyses indicate that women receiving NAC had significantly higher odds of live birth, pregnancy, and ovulation compared to placebo. One meta-analysis reported an almost 3-fold higher odds ratio for live birth (pOR 3.00; 95% CI 1.05–8.60) [35]. In the metabolic domain, RCTs and meta-analyses show that NAC significantly lowered fasting glycemia and total cholesterol; the common therapeutic dosage was typically 1500 mg/day for 6–24 weeks [36].
Resveratrol
Resveratrol in PCOS possesses clinical data regarding endocrine markers and selected periconceptional endpoints. A meta-analysis demonstrated reductions in testosterone, LH, and DHEAS versus placebo. RCTs in PCOS utilized dosages such as 800 mg/day for 60 days and 1000 mg/day for 3 months. Conversely, a pooled analysis found no impact on clinical pregnancy rates compared to placebo, a critical consideration when positioning fertility claims [33, 37].
Melatonin
Melatonin is presented as an adjunctive supplement in PCOS. A meta-analysis of three studies demonstrated a significant impact on clinical pregnancy rates in ART, utilizing regimens of 3 mg from the onset of the cycle or from day 3 until the trigger day. Concurrently, an RCT (n=56) reported decreases in hirsutism, testosterone, hs-CRP, and MDA, alongside increases in total antioxidant capacity (TAC) and total GSH in the cohort receiving melatonin for 12 weeks [34].
Multi-ingredient Formulations
In multi-ingredient formulations, partner nutrients include chromium—indicated as a vital oligoelement for regulating insulin secretion and maintaining normoglycemia—and folic acid, which is frequently deficient in reproductive-aged women with PCOS. Commercial examples highlight specific dosages (e.g., 36 mg vitamin E, 400 µg folate, 40 µg chromium per serving) [30].
Foods for Special Medical Purposes (FSMP)
In the provided materials, medical foods are represented by products designated as "Foods for special medical purposes" or "dietary special medical purposes" intended for the dietary management of women with PCOS (including those seeking to conceive) [31, 38].
Fertilovit® FPCOS
For instance, Fertilovit® FPCOS is described as a food for special medical purposes tailored to the requirements of women with PCOS, comprising inositol, high-dose folic acid, and vitamin D, combined with vitamins, minerals, and omega-3 fatty acids. It explicitly declares the use of MI and DCI isomers in a 40:1 ratio [31]. Regarding administration practice, the product proposes a regimen consisting of a "water-dispersible powder stick + a vitamin-mineral capsule + a fish oil capsule" as a single daily serving, exemplifying the segregation of hydrophilic and lipophilic payloads within a daily routine [31].
Miositogyn
Another example is Miositogyn, described as a dietary food for special medical purposes for the management of menstrual disorders and PCOS, stipulating that it is unsuitable for parenteral use or as a sole source of nourishment and must be used under medical supervision. The label specifies the active ingredient content per sachet (e.g., 2000 mg MI, 600 mg NAC, 400 µg folate) [38].
Recommendations
The design of products targeting the female endocrine-metabolic axis (PCOS, pre-IVF/IVF) should be anchored in robust active components that concurrently possess biological rationale (insulin-ovary axis, redox-mitochondrial dynamics) and clinical evidence, utilizing the simplest feasible dosing formats (e.g., sachets, dispersible powders, lipid capsules) [1–3, 15, 19, 36].
The table below correlates combinations with the most compelling evidence in the provided sources and suggests technological formats compatible with high payloads and a reduction in dose units.
Technologically, if the objective is to amalgamate multiple lipophilic antioxidants (e.g., vitamin E, resveratrol, tocotrienols) into a minimal number of capsules, SEDDS/S-SEDDS constitute a highly logical pathway. They generate fine emulsions within the gastrointestinal tract and are amenable to industrial solidification methods (spray-drying, melt extrusion, adsorption), thereby bolstering both stability and patient compliance [18, 28]. For labile polyphenols, liposomes and phospholipids serve as an adjunctive tool, capable of averting degradation (e.g., protecting resveratrol from light and oxidation), although literature concomitantly stresses the imperative of stability monitoring (aggregation/leakage) and characterization requirements (stability, surface charge, encapsulation efficiency, particle size) [16, 41].
Gaps and Research Directions
The provided sources corroborate that the clinical efficacy of numerous nutraceuticals is heavily circumscribed by poor oral bioavailability. This substantiates the need for continuous investments in advanced delivery technologies (phospholipids, SEDDS, microcarriers, powder-drying techniques) and comparative "formulation vs. formulation" clinical studies [42].
Within the realm of liposomes and nano-/microencapsulation systems, significant developmental risks emerge: liposomal suspensions may aggregate and exhibit payload leakage during long-term storage. Consequently, development documentation must comprehensively encompass assessments of long-term stability, surface charge (zeta potential), encapsulation efficiency, and particle size distribution to mitigate quality and regulatory risks in the functional food and supplement sectors [16, 41].
At the clinical level, not all active ingredients yield uniform conclusions concerning reproductive endpoints. For instance, in the case of resveratrol, a meta-analysis demonstrated no significant effect on clinical pregnancy rates versus placebo despite highly favorable alterations in hormonal and androgenic markers. This intimates the necessity for superior study designs and judicious endpoint selection within the FemTech and reproductive medicine space (distinguishing metabolic outcomes from hard fertility endpoints) [33].
Regarding alpha-lipoic acid (ALA), a distinct caveat was articulated in the literature:
in the absence of reliable evidence, ALA should not be routinely recommended in the clinical management of PCOS (even in conjunction with myo-inositol).
This implies that ALA necessitates a development strategy predicated on more robust clinical data and/or more precise patient stratification, notwithstanding the existence of mechanistic insulin-related rationales (e.g., IRS-1/GLUT-4 pathways) [43, 44].
Finally, in the development of "high-payload" lipid systems, thermodynamic efficacy must be carefully balanced against physiological tolerability. Technological data stipulate that the effective surfactant concentration in SEDDS should generally reside between 30% and 60%. Due to the inherent risk of gastric mucosal irritation and potential cytotoxicity at these levels, this directly impacts the practical payload limits and necessitates the rigorous selection of highly tolerated, food-grade excipients [18].
Thalamati S (2020) Порівняльне дослідження комбінації міо-інозитолу та d-хіро-інозитолу проти метформіну при лікуванні синдрому полікістозних яєчників у жінок із ожирінням та безпліддям. Reproductive Endocrinology. https://doi.org/10.18370/2309-4117.2020.56.96-99
Pustotina O, Myers SH, Unfer V, Rasulova I (2024) The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecologic and Obstetric Investigation. https://doi.org/10.1159/000536163
Brown AM, McCarthy HE (2023) The Effect of CoQ10 supplementation on ART treatment and oocyte quality in older women. Human Fertility. https://doi.org/10.1080/14647273.2023.2194554
Viña I, Viña JR, Carranza M, Mariscal G (2025) Efficacy of N-Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. Nutrients. https://doi.org/10.3390/nu17020284
A dataset of formulation compositions for self-emulsifying drug ... https://www.nature.com/articles/s41597-023-02812-w
Malvi A, Chaturvedi A, Mehta S, et al (2019) A comprehensive overview of role of combined myoinositol and D-chiroinositol (40:1 ratio) therapy in the management of PCOS. New Indian Journal of OBGYN. https://doi.org/10.21276/obgyn.2019.5.2.2
Dinicola S, Unfer V, Facchinetti F, et al (2021) Inositols: From Established Knowledge to Novel Approaches. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms221910575
Ramaraju RLN (2025) Evaluating combined therapy with myoinositol and D-chiro-inositol in infertility management across PCOS phenotypes: a comprehensive retrospective data analysis. International Journal of Reproduction Contraception Obstetrics and Gynecology. https://doi.org/10.18203/2320-1770.ijrcog20253523
Monastra G, Unfer V, Harrath A, Bizzarri M (2017) Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2016.1247797
Isabella R, Raffone E (2012) CONCERN: Does ovary need D-chiro-inositol? Journal of Ovarian Research. https://doi.org/10.1186/1757-2215-5-14
Roseff S, Montenegro M (2020) Лікування інозитолом синдрому полікістозних яєчників має бути науково обґрунтованим і не випадковим. Reproductive Endocrinology. https://doi.org/10.18370/2309-4117.2020.55.94-98
Roseff S, Montenegro M (2020) Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. International Journal of Endocrinology. https://doi.org/10.1155/2020/6461254
Bullmann A, Baran J, Wojciechowska K, et al (2026) The Role of Myo-Inositol in the Management of Metabolic and Reproductive Sequelae of Polycystic Ovary Syndrome: A Comprehensive Review of the Current State of Knowledge. Quality in Sport. https://doi.org/10.12775/qs.2026.51.68504
Facchinetti F, Unfer V, Dewailly D, et al (2020) Inositols in Polycystic Ovary Syndrome: An Overview on the Advances. Trends in endocrinology and metabolism. https://doi.org/10.1016/j.tem.2020.02.002
Giannubilo S, Orlando P, Silvestri S, et al (2018) CoQ10 Supplementation in Patients Undergoing IVF-ET: The Relationship with Follicular Fluid Content and Oocyte Maturity. Antioxidants. https://doi.org/10.3390/antiox7100141
Food-Grade Liposome-Loaded Delivery Systems - PMC - NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC12428440/
Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin. https://www.mdpi.com/1424-8247/15/7/790
Self-Emulsifying Drug Delivery Systems (SEDDS) - MDPI. https://www.mdpi.com/1999-4923/17/1/63
Colazingari S, Treglia M, Najjar R, Bevilacqua A (2013) The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-013-2855-3
Unfer V, Porcaro G (2014) Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Review of Clinical Pharmacology. https://doi.org/10.1586/17512433.2014.925795
Kamenov Z, Gateva A (2020) Inositols in PCOS. Molecules. https://doi.org/10.3390/molecules25235566
Caruana R, Zizzo M, Caldara GF, et al (2024) Anionic Methacrylate Copolymer Microparticles for the Delivery of Myo-Inositol Produced by Spray-Drying: In Vitro and In Vivo Bioavailability. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25073852
Liposomes As Delivery System - Liposoma Nutraceuticals. https://liposomanutraceuticals.com/liposomes-as-delivery-system/
Ma L, Cai L, Hu M, et al (2020) Coenzyme Q10 supplementation of human oocyte in vitro maturation reduces postmeiotic aneuploidies. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2020.04.002
Jiang Y, Han Y, Qiao P, Ren F (2025) Exploring the protective effects of coenzyme Q10 on female fertility. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2025.1633166
Nutrateq Platform Technology | Liposoma Tech. https://www.liposomatechnology.com/platform-technologies/nutrateq/
Behnam S Untitled. https://www.protocolforlife.com/wp-content/uploads/2024/10/P3087-Quercetin-Phospholipid-techsheet_ct_amk.pdf
Self-Emulsifying Drug Delivery Systems (SEDDS): An Innovative Approach to Enhance Oral Bioavailability of Poorly Soluble Drugs. https://www.ijpsjournal.com/article/SelfEmulsifying+Drug+Delivery+Systems+SEDDS+An+Innovative+Approach+to+Enhance+Oral+Bioavailability+of+Poorly+Soluble+Drugs
Self-Emulsifying Drug Delivery Systems | Pharmaceutical Technology. https://www.pharmtech.com/view/self-emulsifying-drug-delivery-systems
Poligen Plus. https://www.e-pharma.com/en/products/poligen-plus
Untitled. https://fertilovit.gr/wp-content/uploads/2016/12/Fertilovit-FPCOS.pdf
Andrea Fratter VM Marzia Pellizzato, Stefano Valier, Arrigo Francesco Giuseppe Cicero, Erik Tedesco, Elisa Meneghetti and Federico Benetti Untitled. https://mdpi-res.com/d_attachment/ijms/ijms-20-00669/article_deploy/ijms-20-00669.pdf?version=1549286737
Fadlalmola HA, Elhusein A, Al-Sayaghi KM, et al (2023) Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. The Pan African Medical Journal. https://doi.org/10.11604/pamj.2023.44.134.32404
Nutritional and herbal interventions for polycystic ovary ... - PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12049039/
Thakker D, Raval A, Patel I, Walia R (2015) N-Acetylcysteine for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Obstetrics and Gynecology International. https://doi.org/10.1155/2015/817849
Liu J, Su H, Jin X, et al (2023) The effects of N-acetylcysteine supplement on metabolic parameters in women with polycystic ovary syndrome: a systematic review and meta-analysis. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2023.1209614
Ardehjani NA, Agha-Hosseini M, Nashtaei MS, et al (2024) Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial. Journal of Ovarian Research. https://doi.org/10.1186/s13048-024-01470-9
Elivera UK ElUL and ELU Miositogyn powder with orange flavor x 30 sachets, polycystic ovary syndrome – ELIVERA UK. https://eliveragroup.co.uk/products/miositogyn-powder-with-orange-flavor-x-30-sachets-polycystic-ovary-syndrome
Laganà A, Garzon S, Casarin J, et al (2018) Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends in endocrinology and metabolism. https://doi.org/10.1016/j.tem.2018.09.001
Liproteq Platform Technology | Liposoma Tech. https://www.liposomatechnology.com/platform-technologies/liproteq/
Liposomal Formulations: A Recent Update - PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11769406/
Information A Matrix Science Pharma. https://journals.lww.com/mtsp/fulltext/2024/08010/advancements_in_nutraceutical_delivery_.1.aspx
Lagana A, Monti N, Fedeli V, et al (2022) Does Alpha-lipoic acid improve effects on polycystic ovary syndrome? European Review for Medical and Pharmacological Sciences. https://doi.org/10.26355/eurrev_202202_28116
Santoso B, Rusnaidi, Widjiati (2020) Effect of Alpha Lipoic Acid on Polycystic Ovary Syndrome with Insulin Resistance. Indian Journal of Forensic Medicine & Toxicology. https://doi.org/10.37506/IJFMT.V14I4.11632
